Amyris Is Spending Way Too Much on Manufacturing Costs

Already reeling from the broader market correction, investors appear less willing to extend the benefit of the doubt to Amyris (NASDAQ: AMRS). The synthetic biology company reported fourth-quarter and full-year 2019 operating results that showed little progress where it matters most. Shares tumbled by more than 20% soon after the opening bell on a day when most of the market started off significantly higher.

A closer look at the numbers suggests the drop in share price isn't an overreaction. Although management described big plans for 2020 and beyond, investors would be well served to be more objective about the company's trajectory. Here's what investors need to know about the latest update from Amyris.

Image source: Getty Images.

Source Fool.com